Diva Baggio, Clinical Trials Fellow at UCL, shared a post on X:
“At EHA2026 Dr Wang presents a phase 1 trial of anti-CD5 CAR-T in T-ALL, CTCL and PTCL: promising ORR but a high rate of EBV/CMV reactivation, including EBV+ PTLD: underscoring one of the many therapeutic challenges of T-cell redirecting therapies targeting T-cell lymphoma”
Other articles featuring Diva on OncoDaily.
